ExpreS2ion Biotechnologies - Presentation of Q3 2024
ExpreS2ion Biotechnologies is expected to release its Q3 2024 results on 14 November 2024. Later the same day at 11:00, the company’s CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements during the period in an online live presentation. The management presentation will be followed by a Q&A session.
Besides the financial results and capital situation, further advancement in its development plans for its breast cancer candidate, ES2B-C001, could be in focus. Currently, the company has submitted a CTA application to the Austrian Agency for Health and Food Safety and is awaiting regulatory approval to commence the first-in-human phase I clinical trial. Furthermore, the latest development regarding its pipeline could come into focus. Looking at the recent news, ExpreS2ion Biotechnologies has announced that a term sheet has been entered with one of the largest vaccine manufacturers in the world, Serum Institute of India Private Limited (SIIPL). Upon the execution of a definitive agreement with mutually agreed-upon terms, SIIPL will obtain exclusive licensing rights to develop, manufacture, and commercialize certain malaria vaccine product lines, currently in phase I and phase II clinical development.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 09.03 17 October 2024.
